Winslow Evans & Crocker’s United Therapeutics UTHR Stock Holding History

Winslow Evans & Crocker’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$9K	Hold	58	–	–	﹤0.01%	979
2020 Q3	$6K	Hold	58	–	–	﹤0.01%	858
2020 Q2	$7K	Hold	58	–	–	﹤0.01%	817
2020 Q1	$6K	Hold	58	–	–	﹤0.01%	845
2019 Q4	$6K	Hold	58	–	–	﹤0.01%	957
2019 Q3	$6K	Buy	+58	New	+$4.67K	﹤0.01%	943
2019 Q2	–	Sell	-4	Closed	-$2K	–	1339
2019 Q1	$2K	Buy	+4	New	+$466	﹤0.01%	1259
2016 Q1	–	Sell	-176	Closed	-$27.4K	–	1339
2015 Q4	$27.4K	Buy	176 +126	+252%	+$18.3K	0.01%	669
2015 Q3	$6.56K	Buy	+50	New	+$8.02K	﹤0.01%	971

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Winslow Evans & Crocker's UTHR Position: Q4 2020 in Review

Winslow Evans & Crocker held its United Therapeutics (UTHR) position steady in Q4 2020 at 58 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #979.

Winslow Evans & Crocker first reported a position in UTHR in Q3 2015 and has held it in 9 quarters since. The position peaked at $27.4K in Q4 2015. 356 funds tracked by Wall St. Rank hold UTHR as of Q4 2020.

Winslow Evans & Crocker held 58 shares of United Therapeutics worth $9K as of Q4 2020.
Winslow Evans & Crocker left its United Therapeutics share count unchanged in Q4 2020.
United Therapeutics made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #979 holding.
Winslow Evans & Crocker first reported a position in United Therapeutics in Q3 2015 and has held it in 9 quarters since.
Winslow Evans & Crocker's United Therapeutics position peaked at $27.4K in Q4 2015.
356 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.